FDA Approved: JULUCA — Supplemental Application (ViiV Healthcare Company)

View source ↗

Summary

The FDA approved a supplemental application for JULUCA (dolutegravir and rilpivirine) from ViiV Healthcare, updating its label for HIV-1 treatment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Juluca (dolutegravir + rilpivirine)

Snippet

SUPPL AP for JULUCA (DOLUTEGRAVIR SODIUM AND RILPIVIRINE HYDROCHLORIDE)